Jubilant Therapeutics is set to present promising preliminary clinical findings for its experimental blood cancer drug JBI-802 at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, following the selection of its Phase 1/2 study results for an oral presentation.
The findings point to rapid platelet reductions and sustained hematologic control in patients with essential thrombocythemia (ET) and related myeloproliferative neoplasms (MPNs), offering encouraging early signals for the first-in-class oral dual LSD1/HDAC6 (CoREST) inhibitor.
The ASH meeting will take place December 12–15, 2026, in New Orleans and online.
“We are pleased to have the preliminary clinical data for JBI-802 selected for oral presentation at ASH,” said Daniel O’Connor, President and Chief Executive Officer of Jubilant Therapeutics.
“The abstract data from this ongoing Phase 1/2 study show encouraging early evidence of rapid platelet reductions and hematologic control in patients with ET and related MPNs. We look forward to presenting additional efficacy, safety and molecular data at ASH as we continue to evaluate JBI-802 in these patients.”
The preliminary findings, based on data collected through June 30, 2026, show that all eight patients who began treatment at the 15 mg dose achieved either a greater than 50% reduction in platelet counts or platelet normalization to below 400 × 10⁹/L by Week 3.
The median time to response was just 15 days.
The results also indicate sustained treatment responses. Patients receiving the 15 mg dose maintained platelet normalization for 33, 44 and 46 weeks, respectively, among those with more than 12 weeks of follow-up.
The study also reported encouraging results in patients with elevated white blood cell counts. Seven of 11 patients with leukocytosis receiving the 15 mg dose achieved a complete hematologic response.
Importantly, no dose-limiting toxicities were observed at the 5 mg, 7 mg or 15 mg dose levels.
JBI-802 is being evaluated in an open-label, multicenter Phase 1/2 clinical trial designed to assess its safety, tolerability and preliminary efficacy.
The study includes patients with essential thrombocythemia, polycythemia vera (PV) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) with thrombocytosis who have relapsed, proved refractory to treatment or were intolerant to standard-of-care therapies.
